Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL4824906

N.c1ccc2c(c1)ncc1nc[nH]c12

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.53
CA12 O43570 1/20 0.53
PARP1 P09874 1/20 0.53
ALOX15 P16050 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
CA9 Q16790 1/20 0.53
TNKS2 Q9H2K2 1/20 0.53
KDM4E B2RXH2 2/20 0.44
GPR3 P46089 1/20 0.44
GABRA1 P14867 3/20 0.39
GABRG2 P18507 3/20 0.39
GABRB3 P28472 3/20 0.39
GABRA5 P31644 3/20 0.39
GABRA3 P34903 3/20 0.39
GABRA2 P47869 3/20 0.39
GABRA6 Q16445 2/20 0.39
HDAC6 Q9UBN7 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PRNP P04156 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29508386 0.98 PDPK1 (0.55) PDPK1CA12PARP1ALOX15SMN1; SMN2
SCHEMBL202156 0.98 PDPK1 (0.55) PDPK1CA12PARP1ALOX15SMN1; SMN2
Hydrochloric Acid SCHEMBL4766699 0.96 PDPK1 (0.53) PDPK1CA12PARP1ALOX15SMN1; SMN2
SCHEMBL10427747 0.96 PDPK1 (0.53) PDPK1CA12PARP1ALOX15SMN1; SMN2
Formic Acid SCHEMBL10727380 0.88 PDPK1 (0.50) PDPK1CA12PARP1ALOX15SMN1; SMN2
Formic Acid SCHEMBL10738924 0.87 PDPK1 (0.49) PDPK1CA12PARP1ALOX15SMN1; SMN2
Acetic Acid SCHEMBL10727228 0.87 SMN1; SMN2 (0.49) PDPK1CA12PARP1ALOX15SMN1; SMN2
Acetic Acid SCHEMBL10742452 0.85 SMN1; SMN2 (0.47) PDPK1CA12PARP1ALOX15SMN1; SMN2
Trifluoroacetic Acid SCHEMBL29627985 0.83 PARP1 (0.45) PDPK1CA12PARP1ALOX15SMN1; SMN2
Water SCHEMBL10734174 0.81 PDPK1 (0.40) PDPK1CA12PARP1ALOX15SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610319-B2 Administering imiquimod 3M INNOVATIVE PROPERTIES COMPANY 2003-08-26 US claimed
CN-100372847-C Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-C] quinolin-4-cyano and 1H-imidazo [4,5-C] quinolin-4-carboxamide intermediates TEVA PHARMA (HU) 2008-03-05 CN disclosed
US-7335772-B2 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) 2008-02-26 US disclosed
US-7335772-B2 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) 2008-02-26 US disclosed
EP-1539752-B1 PREPARATION OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES VIA NOVEL IMIDAZO[4,5-C]QUINOLIN-4-CYANO AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-CARBOXAMIDE INTERMEDIATES TEVA GYOGYSZERGYAR ZARTKOERUEE (HU) 2007-03-21 EP disclosed
US-20070060755-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG 2007-03-15 US disclosed
US-7166721-B2 Preparation of 1H-imidazo[4,5-C] quinolin 4-amines via novel 1H-imidazo[4,5-c] quinolin 4-cyano and 1H-imidazo[4,5-c] quinolin 4-carboxamide intermediates TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság (HU) 2007-01-23 US disclosed
US-7153967-B2 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) 2006-12-26 US disclosed
EP-1543002-B1 PREPARATION OF 1H-IMIDAZO 4,5-C|QUINOLIN-4-AMINES VIA1H-IMIDAZO 4,5-C|QUINOLIN-4-PHTHALIMIDE INTERMEDIATES TEVA GYOGYSZERGYAR ZARTKOERUEN (HU) 2006-08-30 EP disclosed
CN-1684963-A Preparation of 1H-imidazo [4, 5-C ] quinolin-4-amines via novel 1H-imidazo [4, 5-C ] quinolin-4-cyano and 1H-imidazo [4, 5-C ] quinolin-4-carboxamide intermediates TEVA PHARMA (HU) 2005-10-19 CN disclosed
US-20050101627-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4 amines via novel 1h-imidazo [4,5-C] quinolin-4-cyano and 1h-imidazo [4,5-C] quinolin-4-carboxamide intermediates TEVA PHARAMCEUTICAL INDUSTRIES LTD TO BIOGAL GYOGYSZERGYAR RT. 2005-05-12 US disclosed
US-6852861-B2 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates BIOGAL GYOGYSZERGYAR RT. (HU) 2005-02-08 US disclosed
US-6841678-B2 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates BIOGAL GYOGYSZERGYAR RT. (HU) 2005-01-11 US disclosed
US-6780873-B2 FOR INDUCING CYTOKINE BIOSYNTHESIS IN ANIMALS, AND IN THE TREATMENT OF DISEASES, INCLUDING VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY 2004-08-24 US disclosed
US-20040138459-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) 2004-07-15 US disclosed
US-20040063743-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) 2004-04-01 US disclosed
EP-0802913-B1 IMIDAZO [4,5-c]QUINOLINE AMINES MINNESOTA MINING & MFG (US) 2000-04-26 EP disclosed
EP-0802913-A1 IMIDAZO 4,5-c]QUINOLINE AMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-10-29 EP disclosed
WO-1996021663-A1 IMIDAZO[4,5-c]QUINOLINE AMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-07-18 WO disclosed
US-5482936-A INDUCE INTERFERON BIOSYNTHESIS IN AN ANIMAL MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101627-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4 amines via novel 1h-imidazo [4,5-C] quinolin-4-cyano and 1h-imidazo [4,5-C] quinolin-4-carboxamide intermediates KDM4C, P2RX4, IL4 PDPK1 1980/4885CA12 3512/4885PARP1 437/4885
US-20070060755-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates TLR7, IL4, P2RY4 PDPK1 2113/4885CA12 3804/4885PARP1 190/4885
US-20040063743-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates IL4, MCM4, CUL4A PDPK1 2127/4885CA12 3644/4885PARP1 523/4885
US-20040138459-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates TLR7, IL4, P2RY4 PDPK1 2154/4885CA12 3757/4885PARP1 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.